Atjaunināt sīkdatņu piekrišanu

E-grāmata: Smallpox Vaccination Program: Public Health in an Age of Terrorism

  • Formāts: 392 pages
  • Izdošanas datums: 06-Sep-2005
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309165235
Citas grāmatas par šo tēmu:
  • Formāts - EPUB+DRM
  • Cena: 68,87 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 392 pages
  • Izdošanas datums: 06-Sep-2005
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309165235
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

December 13, 2002, the president of the United States announced that smallpox vaccination would be offered to some categories of civilians and administered to members of the military and government representatives in high-risk areas of the world. The events that precipitated that historic announcement included a series of terrorist attacks during the 1990s, which culminated in the catastrophic events of 2001. Although preparedness for deliberate attacks with biologic weapons was already the subject of much public health planning, meetings, and publications as the twentieth century neared its end, the events of 2001 led to a steep rise in bioterrorism-related government policies and funding, and in state and local preparedness activities, for example, in public health, health care, and the emergency response and public safety communities. The national smallpox vaccination program is but one of many efforts to improve readiness to respond to deliberate releases of biologic agents. The Institute of Medicine (IOM) Committee on Smallpox Vaccination Program Implementation was convened in October 2002 at the request of the Centers for Disease Control and Prevention (CDC), the federal agency charged with implementing the government's policy of providing smallpox vaccine first to public health and health care workers on response teams, then to all interested health care workers and other first responders, and finally to members of the general public who might insist on receiving the vaccine. The committee was charged with providing "advice to the CDC and the program investigators on selected aspects of the smallpox program implementation and evaluation." The committee met six times over 19 months and wrote a series of brief "letter" reports. The Smallpox Vaccination Program: Public Health in an Age of Terrorism constitutes the committee's seventh and final report, and the committee hopes that it will fulfill three purposes: 1) To serve as an archival document that brings together the six reports addressed to Julie Gerberding, director of CDC, and previously released on line and as short, unbound papers; 2) To serve as a historical document that summarizes milestones in the smallpox vaccination program, and; 3) To comment on the achievement of overall goals of the smallpox vaccination program (in accordance with the last item in the charge), including lessons learned from the program.
EXECUTIVE SUMMARY
References,
7(2)
1 SMALLPDX AND SMALLPDX CONTROL IN THE HISTORICAL CONTEXT 9(13)
A Brief History of Smallpox,
10(1)
Understanding the Disease,
11(8)
References,
19(3)
2 POLICY CONTEXT OF SMALLPDX PREPAREDNESS 22(17)
Steps Toward Readiness for a Smallpox Virus Release,
24(10)
Concluding Observations,
34(1)
References,
35(4)
3 THE IMPLEMENTATION OF THE SMALLPOX VACCINATION PROGRAM 39(42)
Major Milestones and Relevant Events,
41(17)
Noteworthy Features of the Program,
58(2)
Program Challenges,
60(3)
Favorable Outcomes,
63(2)
Concluding Observations,
65(7)
References,
72(9)
4 LESSONS LEARNED FROM THE SMALLPOX VACCINATION PROGRAM 81(30)
Absence of Explicit Scientific and Public Health Rationale for the Program,
81(15)
Outcome Unknown: Has Smallpox Preparedness Been Enhanced?,
96(4)
Concluding Observations,
100(2)
References,
102(9)
APPENDIXES
A RECOMMENDATIONS FROM LETTER REPORTS 1-6
111(12)
Recommendations from Letter Report #1,
111(4)
Recommendations from Letter Report #2,
115(2)
Recommendations from Letter Report #3,
117(1)
Recommendations from Letter Report #4,
118(2)
Recommendations from Letter Report #5,
120(1)
Recommendations from Letter Report #6,
121(2)
B REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S SMALLPDX VACCINATION PROGRAM IMPLEMENTATION, LETTER REPORT #1
123(39)
Background Information and Committee Process,
124(3)
Summary of Key Messages,
127(1)
General Considerations,
127(9)
Specific Considerations,
136(23)
Closing Remarks,
159(1)
References,
159(3)
C REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S SMALLPDX VACCINATION PROGRAM IMPLEMENTATION, LETTER REPORT #2
162(33)
Current Program Context,
163(1)
Summary of Key Messages,
164(1)
Overarching Issues: Preparedness and Evaluation,
164(6)
Programmatic Issues,
170(22)
Concluding Remarks,
192(1)
References,
192(3)
D REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S SMALLPDX VACCINATION PROGRAM IMPLEMENTATION, LETTER REPORT #3
195(8)
General Comments,
196(1)
Considerations for Next Steps in the Vaccination Program,
197(3)
Comments About the Guidance,
200(1)
References,
201(2)
E REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S SMALLPDX VACCINATION PROGRAM IMPLEMENTATION, LETTER REPORT #4
203(49)
Integrating Smallpox Preparedness into Overall Public Health Preparedness,
204(18)
Vaccination of Members of the General Public Who Insist on Receiving Smallpox Vaccine,
222(4)
Selected Aspects of Smallpox Vaccination Program Implementation,
226(16)
Concluding Remarks,
242(1)
References,
243(5)
Letter Report #4, Appendix Summary of Recommendations: Integrating Smallpox Preparedness into Overall Public Health Preparedness,
248(1)
Vaccination of Members of the General Public Who Insist on Receiving Smallpox Vaccine,
249(1)
Selected Aspects of Smallpox Vaccination Program Implementation,
250(2)
F REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S SMALLPDX VACCINATION PROGRAM IMPLEMENTATION, LETTER REPORT #5
252(33)
Introduction,
253(2)
General Parameters of Four Scenarios to Assess Smallpox Readiness Indicators,
255(7)
Comments About the Draft Readiness Indicators,
262(12)
Concluding Remarks,
274(1)
References,
275(10)
G REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S SMALLPDX VACCINATION PROGRAM IMPLEMENTATION, LETTER REPORT #6
285(44)
Introduction,
286(2)
Integrating Public Health into Disaster Preparedness and Response: Conceptual Issues,
288(4)
Challenges and Opportunities Inherent in Integrating Public Health into a Broader Field,
292(7)
The Evidence Base from Disaster Research and Practice,
299(5)
Learning from the Public Health Response to Proxy Events,
304(4)
Usefulness of Modeling,
308(4)
Usefulness of Exercises,
312(8)
Concluding Remarks,
320(1)
References,
321(8)
H AGENDAS FOR COMMITTEE INFORMATION-GATHERING MEETINGS
329(13)
I COMMITTEE BIOSKETCHES
342(7)
INDEX 349
Committee on Smallpox Vaccination Program Implementation, Alina Baciu, Andrea Pernack Anason, Kathleen Stratton, and Brian Strom, Editors